# US 2021/0275688 A1 · Methods and compositions for inhibiting oxidative stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275688 A1
- Document ID: US20210275688A1
- Status: Published application
- Kind: A1
- Application number: 17/206,212
- Filed: 2021-03-19
- Published: 2021-09-09
- Earliest claimed: 2013-10-29
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Constance L. Cepko; Wenjun Xiong
- Web page: https://patentgrep.com/patent/US20210275688A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 38/1709: {from mammals}
- A61K 38/446: {Superoxide dismutase (1.15)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 27/02: Ophthalmic agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of an agent, e.g., a nucleic acid molecule, which increases the expression and/or activity of an antioxidant defense protein.

## Claims

### Claim 1

A method for treating or preventing retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
wherein the pharmaceutical composition comprises a recombinant adeno-associated virus (AAV) comprising a promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for promoting photoreceptor survival and/or function and a pharmaceutically acceptable carrier for intraocular administration,
wherein the promoter is a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter,
wherein the recombinant AAV is an AAV8 or AAV 2/8 recombinant AAV, and
wherein the pharmaceutical composition is formulated for intraocular administration, thereby treating or preventing retinitis pigmentosa in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the promoter is selected from the group consisting of an Nrl promoter, a Crx promoter, a Rax promoter, a cone opsin promoter, an interphotoreceptor retinoid binding protein (IRBP156) promoter, a rhodopsin kinase (RK) promoter, a neural leucine zipper (NRLL) promoter, a cone arrestin promoter, a Cabp5 promoter, a Cralbp promoter, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises a viscosity inducing agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein the intraocular administration is selected from the group consisting of intravitreal, subretinal, subconjunctival, sub-tenon, periocular, retrobulbar, suprachoroidal, and intrascleral administration.

### Claim 5

A method for treating or preventing retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) comprising a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for prolonging the viability of a photoreceptor cell, and a pharmaceutically acceptable carrier for intraocular administration,
wherein the pharmaceutical composition is formulated for intraocular administration, thereby treating or preventing retinitis pigmentosa in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the AAV vector is an AAV 2/5 or an AAV 2/8 vector.

### Claim 7 (depends on 5)

The method of claim 5, wherein the promoter is selected from the group consisting of an Nrl promoter, a Crx promoter, a Rax promoter, a cone opsin promoter, an interphotoreceptor retinoid binding protein (IRBP 156) promoter, a rhodopsin kinase (RK) promoter, a neural leucine zipper (NRLL) promoter, a cone arrestin promoter, a Cabp5 promoter, a Cralbp promoter, and combinations thereof.

### Claim 8 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition further comprises a viscosity inducing agent.

### Claim 9 (depends on 5)

The method of claim 5, wherein the intraocular administration is selected from the group consisting of intravitreal, subretinal, subconjunctival, sub-tenon, periocular, retrobulbar, suprachoroidal, and intrascleral administration.

### Claim 10

A method for prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
wherein the pharmaceutical composition comprises a recombinant adeno-associated virus (AAV) comprising a promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for promoting photoreceptor survival and/or function and a pharmaceutically acceptable carrier for intraocular administration,
wherein the promoter is a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter,
wherein the recombinant AAV is an AAV8 or AAV 2/8 recombinant AAV, and
wherein the pharmaceutical composition is formulated for intraocular administration, thereby prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the promoter is selected from the group consisting of an Nrl promoter, a Crx promoter, a Rax promoter, a cone opsin promoter, an interphotoreceptor retinoid binding protein (IRBP 156) promoter, a rhodopsin kinase (RK) promoter, a neural leucine zipper (NRLL) promoter, a cone arrestin promoter, a Cabp5 promoter, a Cralbp promoter, and combinations thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the pharmaceutical composition further comprises a viscosity inducing agent.

### Claim 13 (depends on 10)

The method of claim 10, wherein the intraocular administration is selected from the group consisting of intravitreal, subretinal, subconjunctival, sub-tenon, periocular, retrobulbar, suprachoroidal, and intrascleral administration.

### Claim 14

A method for prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraocular administration,
wherein the pharmaceutical composition comprises an adeno-associated virus (AAV) comprising a retinal pigment epithelial-specific promoter, a rod-specific promoter, a cone-specific promoter, or a rod- and cone-specific promoter operably linked to a nucleic acid molecule encoding nuclear factor erythroid 2-like 2 (Nrf2) in an amount effective for prolonging the viability of the photoreceptor cell, and a pharmaceutically acceptable carrier for intraocular administration,
wherein the pharmaceutical composition is formulated for intraocular administration, thereby prolonging the viability of a photoreceptor cell compromised by retinitis pigmentosa in the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the AAV vector is an AAV 2/5 or an AAV 2/8 vector.

### Claim 16 (depends on 14)

The method of claim 14, wherein the promoter is selected from the group consisting of an Nrl promoter, a Crx promoter, a Rax promoter, a cone opsin promoter, an interphotoreceptor retinoid binding protein (IRBP156) promoter, a rhodopsin kinase (RK) promoter, a neural leucine zipper (NRLL) promoter, a cone arrestin promoter, a Cabp5 promoter, a Cralbp promoter, and combinations thereof.

### Claim 17 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition further comprises a viscosity inducing agent.

### Claim 18 (depends on 14)

The method of claim 14, wherein the intraocular administration is selected from the group consisting of intravitreal, subretinal, subconjunctival, sub-tenon, periocular, retrobulbar, suprachoroidal, and intrascleral administration.
